We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $499M
1-Year Est. Return 186.05%
This Fund
S&P 500
This Quarter Est. Return
+30.53%
1 Year Est. Return
+186.05%
3 Year Est. Return
+672.09%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$706M
AUM Growth
+$74.9M
Cap. Flow
+$18.2M
Cap. Flow %
2.57%
Top 10 Hldgs %
71.67%
Holding
75
New
24
Increased
13
Reduced
7
Closed
20

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$40.9M
2
LLY icon
Eli Lilly
LLY
+$20.8M
3
VKTX icon
Viking Therapeutics
VKTX
+$20.3M
4
QURE icon
uniQure
QURE
+$14.1M
5
CDTX
Cidara Therapeutics
CDTX
+$11.4M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$40.4M
2
MRUS
Merus
MRUS
+$27.9M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21.6M
4
BSX icon
Boston Scientific
BSX
+$17.9M
5
ARGX icon
argenx
ARGX
+$11.7M

Sector Composition

Rank Sector Weight
1 Healthcare 84.71%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNAM
26
DELISTED
Avidity Biosciences
RNAM
$4.34M 0.61%
60,100
-50,000
-45% -$3.23M
SRRK icon
27
Scholar Rock
SRRK
$5.75B
$4.24M 0.6%
96,285
– –
RAPP
28
Rapport Therapeutics
RAPP
$2.01B
$4.2M 0.6%
138,508
+73,900
+114% +$2.05M
PROK icon
29
ProKidney
PROK
$334M
$4.12M 0.58%
+1,838,411
New +$4.83M
ASND icon
30
Ascendis Pharma A/S
ASND
$16.1B
$3.78M 0.54%
17,740
+5,500
+45% +$1.14M
ABBV icon
31
AbbVie
ABBV
$431B
$3.31M 0.47%
14,500
– –
BLTE
32
Belite Bio
BLTE
$6.31B
$2.88M 0.41%
+17,989
New +$2.13M
ROIV icon
33
Roivant Sciences
ROIV
$25B
$2.82M 0.4%
+129,800
New +$2.56M
TVTX icon
34
Travere Therapeutics
TVTX
$5.22B
$2.7M 0.38%
70,700
+39,800
+129% +$1.29M
DRUG
35
Bright Minds Biosciences
DRUG
$770M
$2.61M 0.37%
+33,407
New +$2.23M
UTHR icon
36
United Therapeutics
UTHR
$21.9B
$2.44M 0.35%
5,000
– –
SLNO
37
CALL
DELISTED
Soleno Therapeutics
SLNO
$2.31M 0.33%
+50,000
New +$2.74M
PTGX icon
38
Protagonist Therapeutics
PTGX
$8.84B
$2M 0.28%
22,951
– –
UPB
39
Upstream Bio Inc
UPB
$370M
$1.86M 0.26%
+68,653
New +$1.71M
XENE icon
40
Xenon Pharmaceuticals
XENE
$6.2B
$1.79M 0.25%
40,000
– –
OCUL icon
41
Ocular Therapeutix
OCUL
$1.91B
$1.71M 0.24%
141,061
– –
BBIO icon
42
BridgeBio Pharma
BBIO
$16.1B
$1.56M 0.22%
20,400
– –
BTSG icon
43
BrightSpring Health Services
BTSG
$12.5B
$1.56M 0.22%
41,600
– –
PEPG icon
44
PepGen
PEPG
$131M
$1.34M 0.19%
+205,324
New +$1.07M
ABVX
45
CALL
Abivax
ABVX
$10.9B
$1.34M 0.19%
+9,900
New +$1.08M
CELC icon
46
Celcuity
CELC
$4.53B
$1.29M 0.18%
+12,900
New +$1.06M
KNSA icon
47
Kiniksa Pharmaceuticals
KNSA
$5.95B
$1.2M 0.17%
29,200
– –
OCUL icon
48
CALL
Ocular Therapeutix
OCUL
$1.91B
$1.03M 0.15%
+85,200
New +$1.03M
NUVL
49
DELISTED
Nuvalent
NUVL
$815K 0.12%
+8,100
New +$799K
AVTX icon
50
Avalo Therapeutics
AVTX
$965M
$755K 0.11%
+41,570
New +$702K
1
2
3

Similar funds

MIP
Marietta Investment Partners Milwaukee, Wisconsin $499M AUM 41.06% 1-Year Est. Return
H2CM
H/2 Credit Manager Stamford, Connecticut $500M AUM 24.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
KCL
KR Capital LP New York City, New York $499M AUM
PPC
Park Place Capital Homewood, Alabama $499M AUM 14.38% 1-Year Est. Return
HIC
Holderness Investments Company Greensboro, North Carolina $498M AUM 34.39% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $498M AUM 20.41% 1-Year Est. Return

Artia Global Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Artia Global Partners held 75 positions worth $706M, up 12% from $631M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Artia Global Partners's Q4 2025 filing shows 24 new, 13 increased, 7 reduced and 20 closed positions. Its largest new stake was Cidara Therapeutics: 70,824 shares worth $15.6M. The largest sale was Verona Pharma, an estimated $40.4M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 86% a quarter earlier, followed by Financials.

  • Artia Global Partners's largest Q4 2025 buy was Cidara Therapeutics: 70,824 shares worth $15.6M.
  • Artia Global Partners added most to Abivax in Q4 2025, an estimated $40.9M increase.
  • Artia Global Partners's biggest Q4 2025 reduction was argenx, cutting an estimated $11.7M.
  • Artia Global Partners fully exited Verona Pharma in Q4 2025, selling an estimated $40.4M.
  • Artia Global Partners's ten largest holdings make up 72% of its $706M portfolio in Q4 2025.
  • Artia Global Partners opened 24 new positions and closed 20 in Q4 2025.
  • Artia Global Partners's portfolio value rose 12% quarter-over-quarter to $706M.

Based on Artia Global Partners's 13F filing for Q4 2025, filed 17 Feb 2026.